Denali Therapeutics Inc
DNLI
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.87B
Close$
$0.96
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.87 Billion |
|---|---|
| Enterprise Value | $3.70 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.97 |
| Beta | 1 |
| Outstanding Shares | 187,314,501 |
Return
| Return on Equity | -61.24% |
|---|---|
| Return on Assets | -44.17% |
| Return on Invested Capital | -49.99% |
Valuation & Multiples
| P/E Ratio | -8.59 |
|---|---|
| PEG | -310.53 |
| Price to Sales | - |
| Price to Book Ratio | 6.21 |
| Enterprise Value to Revenue | 1026.22 |
| Enterprise Value to EBIT | -6.93 |
| Enterprise Value to Net Income | -8 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$2.15 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.69
Average shareholder expectationRevenue Estimate
$12.31 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 49.34% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 27.89%▼ 56.13% |
|---|---|
| Total Invested | $1.34B▼ 52.55% |
| Investors Holding | 112▼ 169.00% |
ESG Score
No data
About Denali Therapeutics Inc
CEO: Ryan Watts